Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia
This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) . The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T c...
Gespeichert in:
| Veröffentlicht in: | Zhōnghuá xuèyèxué zázhì 2022-08, Vol.43 (8), p.651 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 651 |
| container_title | Zhōnghuá xuèyèxué zázhì |
| container_volume | 43 |
| creator | Song, F M Hu, Y X Zhang, M M Wu, W W Xu, H J Zhang, H S Huang, H Wei, G Q |
| description | This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) .
The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T cells in the First Affiliated Hospital of Zhejiang University School of Medicine from February 2020 to July 2021 were analyzed.
Cytokine release syndrome occurred in all patients, and 63.4% (26/41) were grades 1-2. Immune effector cell-associated neurotoxicity syndrome developed in three patients. On median day 15 (9-47) , the complete remission rate was 95.1% (39/41) , of which 38 patients tested negative for bone marrow minimal residual disease detected by flow cytometry. Among the 39 patients with complete remission, 17 patients did not receive further treatment, and 70.6% (12/17) remained in remission at the end of follow-up, with a progression-free survival of 11.6 months of the two patients with the earliest i |
| doi_str_mv | 10.3760/cma.j.issn.0253-2727.2022.08.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2770479327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2770479327</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-c03ef1941ad15562f62d93d022048d03f10478f6295ccaca568f9e8e7775a7343</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhH0A0ar0LyAfe0nqRxInx1KeUiUkKOdo66ypIS9iRyhc-eOkUDitdjT7aWcIWXAWSpWwpa4gfA2tc3XIRCwDoYQKBRMiZGnIWHJCpv_6hMydszsWc5mkUrIzMpGJYhmPsin5egKDfqBQFxSNsRr0QBtD930Ftf3Egq6veBZ46F7QH7bVY7ClGsvSUVvTFrzF2jv6Yf2edlhC67BYdmg60L7pRrDuPdLLnxNaDlW7b3YlOG81LbF_w8rCOTk1UDqcH-eMPN9cb9d3webh9n692gQtF4kPNJNoeBZxKHgcJ8IkoshkMYZmUVowaTiLVDqqWazHGBAnqckwRaVUDEpGckYWv9y2a957dD6vrDv8BTU2vcuFUiMhk0KN1oujtd9VWORtZyvohvyvOPkN6BBzvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2770479327</pqid></control><display><type>article</type><title>Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Song, F M ; Hu, Y X ; Zhang, M M ; Wu, W W ; Xu, H J ; Zhang, H S ; Huang, H ; Wei, G Q</creator><creatorcontrib>Song, F M ; Hu, Y X ; Zhang, M M ; Wu, W W ; Xu, H J ; Zhang, H S ; Huang, H ; Wei, G Q</creatorcontrib><description>This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) .
The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T cells in the First Affiliated Hospital of Zhejiang University School of Medicine from February 2020 to July 2021 were analyzed.
Cytokine release syndrome occurred in all patients, and 63.4% (26/41) were grades 1-2. Immune effector cell-associated neurotoxicity syndrome developed in three patients. On median day 15 (9-47) , the complete remission rate was 95.1% (39/41) , of which 38 patients tested negative for bone marrow minimal residual disease detected by flow cytometry. Among the 39 patients with complete remission, 17 patients did not receive further treatment, and 70.6% (12/17) remained in remission at the end of follow-up, with a progression-free survival of 11.6 months of the two patients with the earliest i</description><identifier>ISSN: 0253-2727</identifier><identifier>DOI: 10.3760/cma.j.issn.0253-2727.2022.08.006</identifier><identifier>PMID: 36709149</identifier><language>chi</language><publisher>China</publisher><subject>Antigens, CD19 ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy, Adoptive - adverse effects ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Receptors, Chimeric Antigen - therapeutic use ; T-Lymphocytes</subject><ispartof>Zhōnghuá xuèyèxué zázhì, 2022-08, Vol.43 (8), p.651</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36709149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, F M</creatorcontrib><creatorcontrib>Hu, Y X</creatorcontrib><creatorcontrib>Zhang, M M</creatorcontrib><creatorcontrib>Wu, W W</creatorcontrib><creatorcontrib>Xu, H J</creatorcontrib><creatorcontrib>Zhang, H S</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Wei, G Q</creatorcontrib><title>Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia</title><title>Zhōnghuá xuèyèxué zázhì</title><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><description>This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) .
The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T cells in the First Affiliated Hospital of Zhejiang University School of Medicine from February 2020 to July 2021 were analyzed.
Cytokine release syndrome occurred in all patients, and 63.4% (26/41) were grades 1-2. Immune effector cell-associated neurotoxicity syndrome developed in three patients. On median day 15 (9-47) , the complete remission rate was 95.1% (39/41) , of which 38 patients tested negative for bone marrow minimal residual disease detected by flow cytometry. Among the 39 patients with complete remission, 17 patients did not receive further treatment, and 70.6% (12/17) remained in remission at the end of follow-up, with a progression-free survival of 11.6 months of the two patients with the earliest i</description><subject>Antigens, CD19</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>T-Lymphocytes</subject><issn>0253-2727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtPwzAQhH0A0ar0LyAfe0nqRxInx1KeUiUkKOdo66ypIS9iRyhc-eOkUDitdjT7aWcIWXAWSpWwpa4gfA2tc3XIRCwDoYQKBRMiZGnIWHJCpv_6hMydszsWc5mkUrIzMpGJYhmPsin5egKDfqBQFxSNsRr0QBtD930Ftf3Egq6veBZ46F7QH7bVY7ClGsvSUVvTFrzF2jv6Yf2edlhC67BYdmg60L7pRrDuPdLLnxNaDlW7b3YlOG81LbF_w8rCOTk1UDqcH-eMPN9cb9d3webh9n692gQtF4kPNJNoeBZxKHgcJ8IkoshkMYZmUVowaTiLVDqqWazHGBAnqckwRaVUDEpGckYWv9y2a957dD6vrDv8BTU2vcuFUiMhk0KN1oujtd9VWORtZyvohvyvOPkN6BBzvA</recordid><startdate>20220814</startdate><enddate>20220814</enddate><creator>Song, F M</creator><creator>Hu, Y X</creator><creator>Zhang, M M</creator><creator>Wu, W W</creator><creator>Xu, H J</creator><creator>Zhang, H S</creator><creator>Huang, H</creator><creator>Wei, G Q</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20220814</creationdate><title>Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia</title><author>Song, F M ; Hu, Y X ; Zhang, M M ; Wu, W W ; Xu, H J ; Zhang, H S ; Huang, H ; Wei, G Q</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-c03ef1941ad15562f62d93d022048d03f10478f6295ccaca568f9e8e7775a7343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2022</creationdate><topic>Antigens, CD19</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>T-Lymphocytes</topic><toplevel>online_resources</toplevel><creatorcontrib>Song, F M</creatorcontrib><creatorcontrib>Hu, Y X</creatorcontrib><creatorcontrib>Zhang, M M</creatorcontrib><creatorcontrib>Wu, W W</creatorcontrib><creatorcontrib>Xu, H J</creatorcontrib><creatorcontrib>Zhang, H S</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Wei, G Q</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, F M</au><au>Hu, Y X</au><au>Zhang, M M</au><au>Wu, W W</au><au>Xu, H J</au><au>Zhang, H S</au><au>Huang, H</au><au>Wei, G Q</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia</atitle><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><date>2022-08-14</date><risdate>2022</risdate><volume>43</volume><issue>8</issue><spage>651</spage><pages>651-</pages><issn>0253-2727</issn><abstract>This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) .
The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T cells in the First Affiliated Hospital of Zhejiang University School of Medicine from February 2020 to July 2021 were analyzed.
Cytokine release syndrome occurred in all patients, and 63.4% (26/41) were grades 1-2. Immune effector cell-associated neurotoxicity syndrome developed in three patients. On median day 15 (9-47) , the complete remission rate was 95.1% (39/41) , of which 38 patients tested negative for bone marrow minimal residual disease detected by flow cytometry. Among the 39 patients with complete remission, 17 patients did not receive further treatment, and 70.6% (12/17) remained in remission at the end of follow-up, with a progression-free survival of 11.6 months of the two patients with the earliest i</abstract><cop>China</cop><pmid>36709149</pmid><doi>10.3760/cma.j.issn.0253-2727.2022.08.006</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-2727 |
| ispartof | Zhōnghuá xuèyèxué zázhì, 2022-08, Vol.43 (8), p.651 |
| issn | 0253-2727 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2770479327 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antigens, CD19 Hematopoietic Stem Cell Transplantation Humans Immunotherapy, Adoptive - adverse effects Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Chimeric Antigen - therapeutic use T-Lymphocytes |
| title | Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A05%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20humanized%20CD19-targeted%20CAR-T%20cells%20in%20patients%20with%20relapsed/refractory%20acute%20B%20cell%20lymphoblastic%20leukemia&rft.jtitle=Zh%C5%8Dnghu%C3%A1%20xu%C3%A8y%C3%A8xu%C3%A9%20z%C3%A1zh%C3%AC&rft.au=Song,%20F%20M&rft.date=2022-08-14&rft.volume=43&rft.issue=8&rft.spage=651&rft.pages=651-&rft.issn=0253-2727&rft_id=info:doi/10.3760/cma.j.issn.0253-2727.2022.08.006&rft_dat=%3Cproquest_pubme%3E2770479327%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2770479327&rft_id=info:pmid/36709149&rfr_iscdi=true |